A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence-Reference-Cited by-同舟云学术

A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence

Published:2023-05-17 Issue:10 Volume:15 Page:2791
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Moroney James¹,Trivella Juan²,George Ben³,White Sarah B.¹

Affiliation:

1. Division of Vascular and Interventional Radiology, Department of Radiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA

2. Division of Gastroenterology and Hepatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA

3. Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA

Abstract

Primary liver cancer is the sixth most common cancer worldwide and the third leading cause of cancer-related death. Conventional therapies offer limited survival benefit despite improvements in locoregional liver-directed therapies, which highlights the underlying complexity of liver cancers. This review explores the latest research in primary liver cancer therapies, focusing on developments in genomics, molecular biomarkers, and artificial intelligence. Attention is also given to ongoing research and future directions of immunotherapy and locoregional therapies of primary liver cancers.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/10/2791/pdf

Reference186 articles.

1. Worldwide Cancer Data|World Cancer Research Fund International (2023, April 14). WCRF International. Available online: https://www.wcrf.org/cancer-trends/worldwide-cancer-data/.

2. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system: The 2022 update;Reig;J. Hepatol.,2022

3. Hepatocellular carcinoma;Llovet;Nat. Rev. Dis. Prim.,2021

4. Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models;Doussot;J. Am. Coll. Surg.,2015

5. Transarterial Therapies for the Treatment of Intrahepatic Cholangiocarcinoma;Zechlinski;Semin. Interv. Radiol.,2013

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and feasibility of laparoscopic radical resection for bismuth types III and IV hilar cholangiocarcinoma: a single-center experience from China;Frontiers in Oncology;2023-12-18